318 related articles for article (PubMed ID: 26155391)
21. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
23. PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.
Four M; Cacheux V; Tempier A; Platero D; Fabbro M; Marin G; Leventoux N; Rigau V; Costes-Martineau V; Szablewski V
Hematol Oncol; 2017 Dec; 35(4):487-496. PubMed ID: 27966264
[TBL] [Abstract][Full Text] [Related]
24. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia.
Yang K; Xu J; Liu Q; Li J; Xi Y
Pathol Res Pract; 2019 Feb; 215(2):265-271. PubMed ID: 30466764
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
26. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
28. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
Wan WZ; Zhang P; Zeng XY; Zhou H; Lin Y; Xiong Z; Zhang RZ; Liu WZ; Han Y; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep; 22(9):848-855. PubMed ID: 31550824
[No Abstract] [Full Text] [Related]
29. Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response.
Pantaleo MA; Tarantino G; Agostinelli C; Urbini M; Nannini M; Saponara M; Castelli C; Stacchiotti S; Fumagalli E; Gatto L; Santini D; De Leo A; Marafioti T; Akarca A; Sabattini E; Pession A; Ardizzoni A; Indio V; Astolfi A
Oncoimmunology; 2019; 8(9):e1617588. PubMed ID: 31428517
[TBL] [Abstract][Full Text] [Related]
30. Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors.
Lagarde P; Pérot G; Kauffmann A; Brulard C; Dapremont V; Hostein I; Neuville A; Wozniak A; Sciot R; Schöffski P; Aurias A; Coindre JM; Debiec-Rychter M; Chibon F
Clin Cancer Res; 2012 Feb; 18(3):826-38. PubMed ID: 22167411
[TBL] [Abstract][Full Text] [Related]
31. PD-1/PD-L1 blockade rescue exhausted CD8+ T cells in gastrointestinal stromal tumours via the PI3K/Akt/mTOR signalling pathway.
Zhao R; Song Y; Wang Y; Huang Y; Li Z; Cui Y; Yi M; Xia L; Zhuang W; Wu X; Zhou Y
Cell Prolif; 2019 May; 52(3):e12571. PubMed ID: 30714229
[TBL] [Abstract][Full Text] [Related]
32. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
[TBL] [Abstract][Full Text] [Related]
33. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
[TBL] [Abstract][Full Text] [Related]
34. Which is the optimal risk stratification system for surgically treated localized primary GIST? Comparison of three contemporary prognostic criteria in 171 tumors and a proposal for a modified Armed Forces Institute of Pathology risk criteria.
Goh BK; Chow PK; Yap WM; Kesavan SM; Song IC; Paul PG; Ooi BS; Chung YF; Wong WK
Ann Surg Oncol; 2008 Aug; 15(8):2153-63. PubMed ID: 18546045
[TBL] [Abstract][Full Text] [Related]
35. Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.
Lartigue L; Neuville A; Lagarde P; Brulard C; Rutkowski P; Dei Tos P; Wardelmann E; Debiec-Rychter M; Italiano A; Coindre JM; Chibon F
Eur J Cancer; 2015 Jan; 51(1):75-83. PubMed ID: 25466504
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma.
Ibrahiem AT; Eladl E; Toraih EA; Fawzy MS; Abdelwahab K; Elnaghi K; Emarah Z; Shaalan AAM; Ehab Z; Soliman NA
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673047
[TBL] [Abstract][Full Text] [Related]
37. Clinical Significance of
Uhercik M; Sanders AJ; Owen S; Davies EL; Sharma AK; Jiang WG; Mokbel K
Anticancer Res; 2017 Aug; 37(8):4249-4254. PubMed ID: 28739716
[TBL] [Abstract][Full Text] [Related]
38. NK cells and T cells cooperate during the clinical course of colorectal cancer.
Sconocchia G; Eppenberger S; Spagnoli GC; Tornillo L; Droeser R; Caratelli S; Ferrelli F; Coppola A; Arriga R; Lauro D; Iezzi G; Terracciano L; Ferrone S
Oncoimmunology; 2014; 3(8):e952197. PubMed ID: 25610741
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
[TBL] [Abstract][Full Text] [Related]
40. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
